<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Everolimus Safe and Effective for Advanced pNET: Final Results of RADIANT-3</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-16</style></pages><abstract><style  face="normal" font="default" size="100%">Final overall survival and safety results of the phase 3 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor trial [RADIANT-3; NCT00412061] have bolstered previous findings that everolimus is effective and safe in the treatment of advanced pancreatic neuroendocrine tumors.</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>